ReviewCureus2025
The Future of Bladder Cancer Therapies: Integrating Hydrogel Scaffolds for Epigenetic Regulator Delivery.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Steroidogenesis is associated with bladder cancer progression via reprogramming the metabolic landscape of the tumor immune microenvironment.Discover oncology · 2026Article
- Functional hydrogel biomaterials for urological diagnosis and treatment-design strategies and application progress: a review.Journal of materials science. Materials in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urine rapidly dilutes and eliminates intravesical chemotherapies, making non-muscle-invasive bladder cancer (NMIBC) a clinical challenge. Reverse thermal hydrogels, mucoadhesive polymers, and tissue-engineered scaffolds have been developed to improve dwell time and target drug delivery. Recent Food and Drug Administration-approved hydrogel formulations have achieved high complete response rates in low-grade intermediate-risk NMIBC. At the same time, dysregulated epigenetic regulators such as lysine demethylase 6A and enhancer of zeste homolog 2, as well as methylation signatures detectable in urine, are revealing new therapeutic and diagnostic avenues. This narrative review synthesizes evidence on hydrogel-based delivery and scaffolding, arguing that combining sustained-release platforms with local epigenetic therapy and regenerative scaffolds represents the next frontier in NMIBC treatment, potentially reducing recurrence while improving bladder preservation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.